A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical trial NCT03135262 · TERMINATED
Trial details
- NCT number
- NCT03135262
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-15
- Primary completion
- 2020-04-30
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.